著者
Takeshi Yamauchi Yasuhiko Sakata Masanobu Miura Soichiro Tadaki Ryoichi Ushigome Kenjiro Sato Takeo Onose Kanako Tsuji Ruri Abe Takuya Oikawa Shintaro Kasahara Kotaro Nochioka Jun Takahashi Satoshi Miyata Hiroaki Shimokawa on behalf of the CHART-2 Investigators
出版者
日本循環器学会
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
pp.CJ-15-0783, (Released:2015-12-07)
参考文献数
44
被引用文献数
6 25

Background:The prognostic impact of new-onset atrial fibrillation (AF) is not fully elucidated.Methods and Results:We examined 4,818 consecutive stage C/D chronic heart failure (CHF) patients in the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 (CHART-2) Study (n=10,219). At enrollment, 1,859 (38.6%) of them had AF. Compared with the 2,953 patients without AF, AF patients were characterized by higher age (71 vs. 68 years), lower estimated glomerular filtration rate (58.9 vs. 61.9 ml/min/1.73 m2), higher brain natriuretic peptide (152 vs. 74.5 pg/ml), similar left ventricular ejection fraction (56.8 vs. 56.5%), and a similar prescription rate of β-blockers (48.1 vs. 50.6%) and renin-angiotensin system (RAS) inhibitors (72.9 vs. 71.6%). Among the patients without AF at enrollment, 106 (3.6%) developed new AF during the median 3.2-year follow-up, which was associated with increased mortality (adjusted hazard ratio, 1.72; P=0.013). In contrast, neither paroxysmal nor chronic AF at enrollment was associated with increased mortality. The mortality rate was significantly high in the first year after the onset of new AF. On inverse probability of treatment weighting analysis using propensity score, RAS inhibitors and statins were associated with reduced incidence of new AF, and diuretics were associated with increase of new AF.Conclusions:Onset of new AF, but not a history of AF, is associated with increased mortality in CHF patients, especially in the first year.
著者
Hiroharu KATAOKA Susumu MIYAMOTO Kuniaki OGASAWARA Koji IIHARA Jun C. TAKAHASHI Jyoji NAKAGAWARA Tooru INOUE Etsuro MORI Akira OGAWA On Behalf of the JET-2 Investigators
出版者
社団法人 日本脳神経外科学会
雑誌
Neurologia medico-chirurgica (ISSN:04708105)
巻号頁・発行日
vol.55, no.6, pp.460-468, 2015 (Released:2015-06-15)
参考文献数
19
被引用文献数
3 49

The purpose of this study is to determine the true threshold of cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) for subsequent ischemic stroke without extracranial-intracranial (EC-IC) bypass surgery in patients with hemodynamic ischemia due to symptomatic major cerebral arterial occlusive diseases. Patients were categorized based on rest CBF and CVR into four subgroups as follows: Group A, 80% < CBF < 90% and CVR < 10%; Group B, CBF < 80% and 10% < CVR < 20%; Group C, 80% < CBF < 90% and 10% < CVR < 20%; and Group D, CBF < 90% and 20% < CVR < 30%. Patients were followed up for 2 years under best medical treatment by the stroke neurologists. Primary and secondary end points were defined as all adverse events and ipsilateral stroke recurrence respectively. A total of 132 patients were enrolled. All adverse events were observed in 9 patients (3.5%/year) and ipsilateral stroke recurrence was observed only in 2 patients (0.8%/year). There was no significant difference among the four subgroups in terms of the rate of both primary and secondary end points. Compared with the medical arm of the Japanese EC-IC bypass trial (JET) study including patients with CBF < 80% and CVR < 10% as a historical control, the incidence of ipsilateral stroke recurrence was significantly lower in the present study. Patients with symptomatic major cerebral arterial occlusive diseases and mild hemodynamic compromise have a good prognosis under medical treatment. EC-IC bypass surgery is unlikely to benefit patients with CBF > 80% or CVR > 10%.
著者
Hiroki Shiomi Takeshi Morimoto Yutaka Furukawa Yoshihisa Nakagawa Ryuzo Sakata Hitoshi Okabayashi Michiya Hanyu Mitsuomi Shimamoto Noboru Nishiwaki Tatsuhiko Komiya Takeshi Kimura on behalf of the CREDO-Kyoto PCI/CABG registry cohort-2 investigators
出版者
日本循環器学会
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
pp.CJ-15-0034, (Released:2015-03-30)
参考文献数
23
被引用文献数
9 36

Background:Studies evaluating long-term (≥5 years) outcome of percutaneous coronary intervention (PCI) compared with coronary artery bypass grafting (CABG) in patients with unprotected left main coronary artery disease (ULMCAD) are still limited, despite concerns for late adverse events after drug-eluting stents implantation.Methods and Results:We identified 1,004 patients with ULMCAD (PCI: n=364, CABG: n=640) among 15,939 patients with first coronary revascularization enrolled in the CREDO-Kyoto PCI/CABG registry cohort-2. The primary outcome measure in the current analysis was a composite of death, myocardial infarction, and stroke (death/MI/stroke). The cumulative 5-year incidence of and the adjusted risk for death/MI/stroke were significantly higher in the PCI group than in the CABG group (34.5% vs. 24.1%, log-rank P<0.001, adjusted hazard ratio (HR): 1.48 [95% confidence interval (CI): 1.07–2.05, P=0.02]). The adjusted risks for all-cause death was not significantly different between the 2 groups. Regarding the stratified analysis by the SYNTAX score, the adjusted risk for death/MI/stroke was not significantly different between the 2 groups in patients with low (<23) or intermediate (23–33) SYNTAX score, whereas it was significantly higher in the PCI group than in the CABG group in patients with high (≤33) SYNTAX score.Conclusions:CABG as compared with PCI was associated with better long-term outcome in patients with ULMCAD, especially those with high anatomical complexity.
著者
科学技術政策研究所 第2研究グループ
出版者
科学技術政策研究所 第2研究グループ
巻号頁・発行日
2012-10-25 (Released:2012-11-02)

今年度(2011年度)の調査では、資本金1億円以上で研究開発を行っている3,443社(回答企業1,263社)を対象とし、研究開発支出額や研究開発者数、研究開発活動の成果としての特許やノウハウの創出・管理の状況、主力製品・サービス分野でのイノベーションの実現と収益獲得の現状等のイノベーション・プロセスに係る全体像の把握の他、研究開発活動の国際展開やM&Aの影響、特別試験研究に係る税額控除制度の活用状況について調査した。 今年度調査の結果、昨年度に比べて、社内研究開発費は減少傾向にあり、外部支出研究開発費は増加傾向にあることが明らかになった。また、研究開発成果としての特許出願数も増加していることがわかった。主力製品・サービス分野で技術的な新規性を持つ新製品・サービスを生み出した企業は全体の4分の1強、新工程を生み出した企業は5分の1程度であった。 研究開発の国際展開について、海外に研究開発拠点を持つ企業の割合は昨年度と比べて若干増加している。M&Aについては、M&Aのタイプにかかわらず、他社によるM&Aは新規技術の研究開発の着手等の企業の研究開発活動に影響を与えることが示された。特別試験研究に係る税額控除制度を利用したことがある企業は、回答企業全体の3.4%であった。利用した企業の制度に対する満足度はおおむね高かったが、一方で制度の存在を知らない企業、知っていても利用制限事項に抵触していて利用できなかった企業等が数多くあることが明らかとなった。
著者
Jury KIM Harold L. Jr. SAPP2 Caryn E. PLUMMER2 Dennis E. BROOKS2 Daeyoung KIM Min-Su KIM
出版者
公益社団法人 日本獣医学会
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.12-0059, (Released:2012-06-01)
被引用文献数
3 7

The objective of the study was to examine changes of intraocular pressure (IOP) undergoing anesthesia in Rhesus Macaques (Macaca mulatta) with Laser-induced Ocular Hypertension. Twenty male rhesus macaques (hypertensive glaucoma eye in OD; normal eye in OS) between 6 and 20 years of age were used for the study. The monkeys were anesthetized with ketamine hydrochloride (10 mg/kg intramuscularly) and 1% isoflurane and then IOP in both eyes was measured by a single investigator using a calibrated TonopenTM applanation tonometer (Mentor, Norwell, MA, U.S.A.). The mean IOP with ketamine anesthesia was 36.70 ± 12.04 (right eye: OD) and 15.88 ± 2.84 (left eye: OS). The mean IOP with isoflurane anesthesia was 19.98 ± 6.67 (right eye: OD) and 15.32 ± 2.15 (left eye: OS). Undergoing isoflurane anesthesia, the IOP of OD was significantly decreased. Conclusively, careful examination of IOP is required to prevent unexpected contraindication on glaucoma patient with isoflurane anesthesia.
著者
Ming-Tang CHIOU Chao-Nan LIN Cheng-Yao YANG2 Guan-Shiuan SU Chuen-Fu LIN Tsung-Chou CHANG
出版者
公益社団法人 日本獣医学会
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.12-0044, (Released:2012-06-01)
被引用文献数
1 6

Porcine circovirus type 2 (PCV2) is the primary causative agent of postweaning multisystemic wasting syndrome. Two major PCV2 genotypes, PCV2a and PCV2b, have been identified. To explore the prevalence of different subgroups of PCV2 in Taiwan, 37 PCV2 isolates collected during 2002–2011 were analyzed. The genotypes of the PCV2 isolates collected before 2007 belonged to either PCV2a or PCV2b. However, all of the isolates collected after 2008 were PCV2b. Most of isolates obtained since 2008 have been classified into a novel genotype within subgroup of PCV2b based on complete ORF2 sequence analysis. Moreover, analysis of the PCV2 isolates from the same pig farm but from different years revealed that the viruses shifted from a PCV2b genotype to a novel subgroup of the PCV2b genotype. Collectively, PCV2b was the dominant PCV2 genotype in Taiwan currently and that the viruses have shifted into a new emerging subgroup within the PCV2b genotype.
著者
高木 靖彦 平田 成 橘 省吾 中村 良介 吉川 真 はやぶさ2プリプロジェクトチーム
出版者
日本惑星科学会
雑誌
遊・星・人 : 日本惑星科学会誌 (ISSN:0918273X)
巻号頁・発行日
vol.19, no.1, pp.48-55, 2010-03-25
被引用文献数
1

「はやぶさ」に続く小惑星探査計画「はやぶさ2」が最初に提案されてからの約4年間の経緯と,計画の概要をまとめた.その中で,ミッションの目標と,それに基づき選定された搭載機器の仕様についても簡単に述べる.